Insomnia among coronavirus disease 2019 survivors: A single-center cross-sectional study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
    • Subject Terms:
      COVID-19*/epidemiology ; Sleep Initiation and Maintenance Disorders*/epidemiology; Male ; Female ; Humans ; Cross-Sectional Studies ; SARS-CoV-2 ; Anxiety/epidemiology ; Depression/epidemiology
    • Abstract:
      Since the coronavirus disease 2019 (COVID-19) epidemic, insomnia has become one of the longer COVID-19 symptoms. This study aimed to investigate insomnia among COVID-19 survivors and explore the occurrence and influencing factors of insomnia. A cross-sectional study was performed from December 2022 to February 2023 through an online questionnaire star survey with 8 questions. The insomnia severity index scale (ISI) was used to assess the severity of insomnia. Univariate analysis was used to analyze the factors related to COVID-19 infection. A total of 564 participants (183 males and 381 females) were surveyed in the present study. The prevalence of insomnia was 63.12%. Among these insomnia patients, there were 202 (35.82%) with sub-threshold symptoms, 116 (20.57%) with moderate symptoms, and 38 (6.74%) with severe symptoms. Univariate analysis indicated that there were statistically significant differences in the prevalence of insomnia among COVID-19 survivors of different ages, occupations, and educational levels (P < .05). Of the 356 insomnia patients, 185 (51.97%) did not take any measures against insomnia, while those who took drugs only, physical exercise only, drugs and physical exercise, and other measures were 90 (25.28%), 42 (11.80%), 17 (4.78%), and 22 (6.18%), respectively. Additionally, of the 107 insomnia patients with drug therapy, 17 (15.89%) took estazolam, 16 (14.95%) took alprazolam, 39 (36.45%) took zopiclone, and 35 (32.71%) took other drugs to improve insomnia symptoms. The prevalence of insomnia symptoms remains high among COVID-19 survivors in China. Education level and occupation may be the influencing factors. Unfortunately, most patients with insomnia do not take corresponding treatment measures.
      Competing Interests: The authors have no conflicts of interest to disclose.
      (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
    • References:
      Psychiatry Res. 2020 Oct;292:113297. (PMID: 32707218)
      J Psychosom Res. 2020 Nov;138:110253. (PMID: 32979696)
      Nat Neurosci. 2021 Feb;24(2):168-175. (PMID: 33257876)
      Psychoneuroendocrinology. 2021 Jun;128:105213. (PMID: 33845387)
      Sleep Med. 2022 Mar;91:262-272. (PMID: 34732293)
      J Sleep Res. 2023 Aug;32(4):e13842. (PMID: 36748346)
      Acta Biomed. 2022 Mar 14;93(1):e2022019. (PMID: 35315399)
      Patient Prefer Adherence. 2022 Jul 08;16:1637-1647. (PMID: 35837086)
      J Multidiscip Healthc. 2022 Jan 21;15:137-152. (PMID: 35087274)
      Sleep Med. 2021 Jun;82:104-109. (PMID: 33910159)
      Psychiatry Res. 2021 Nov;305:114243. (PMID: 34673325)
      Eur Psychiatry. 2020 Aug 28;63(1):e77. (PMID: 32854786)
      N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
      Front Aging Neurosci. 2021 Jun 03;13:662786. (PMID: 34149397)
      Ann Diagn Pathol. 2021 Apr;51:151682. (PMID: 33360731)
      Maedica (Bucur). 2022 Mar;17(1):129-133. (PMID: 35733762)
      Open Forum Infect Dis. 2021 Apr 02;8(6):ofab156. (PMID: 34095336)
      Int J Biol Sci. 2022 Jan 1;18(1):386-408. (PMID: 34975340)
      Lancet. 2021 Jan 16;397(10270):220-232. (PMID: 33428867)
      Front Neurol. 2022 Aug 17;13:929480. (PMID: 36062000)
      PLoS One. 2017 Feb 24;12(2):e0170772. (PMID: 28234940)
      PLoS One. 2020 Jul 28;15(7):e0236562. (PMID: 32722711)
      Int J Environ Res Public Health. 2021 Jan 26;18(3):. (PMID: 33530453)
      Psychiatry Res. 2022 Jan;307:114337. (PMID: 34922241)
      PLoS Med. 2021 Sep 28;18(9):e1003773. (PMID: 34582441)
      J Zhejiang Univ Sci B. 2020 May;21(5):343-360. (PMID: 32425000)
      J Intern Med. 2022 Jul;292(1):103-115. (PMID: 35555926)
      Sleep Med. 2022 Mar;91:161-165. (PMID: 33627300)
      Ann N Y Acad Sci. 2021 Feb;1486(1):90-111. (PMID: 33009668)
      Sleep Med. 2001 Jul;2(4):297-307. (PMID: 11438246)
      Scand J Clin Lab Invest. 2023 Apr;83(2):86-94. (PMID: 36752213)
      Sci Adv. 2020 Jul 31;6(31):. (PMID: 32937591)
      Sleep Med. 2020 Nov;75:282-286. (PMID: 32919351)
      Brain Behav. 2021 May;11(5):e02138. (PMID: 33811451)
      Int J Infect Dis. 2020 Feb;91:264-266. (PMID: 31953166)
      Soc Psychiatry Psychiatr Epidemiol. 2021 Dec;56(12):2275-2286. (PMID: 33616693)
      Int J Environ Res Public Health. 2022 Feb 17;19(4):. (PMID: 35206483)
      Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
      Front Public Health. 2021 Jan 21;8:620023. (PMID: 33553099)
      Nat Rev Immunol. 2020 Jun;20(6):363-374. (PMID: 32346093)
      Psychoneuroendocrinology. 2021 Jul;129:105245. (PMID: 33951563)
    • Publication Date:
      Date Created: 20240216 Date Completed: 20240219 Latest Revision: 20240219
    • Publication Date:
      20240219
    • Accession Number:
      PMC10869043
    • Accession Number:
      10.1097/MD.0000000000037311
    • Accession Number:
      38363887